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Abstract 
Allelic imbalance is a common feature of many malignancies. We have measured 
allelic imbalance in genomic DNA from the breast cancer cell lines T47D, MDA-MB-
231, two antiestrogen sensitive (MCF7N and MCF7L) and two resistant MCF7 cell 
lines (MMU2 and LCC9) using single nucleotide polymorphism (SNP) 
oligonucleotide microarrays. DNA from MCF7L and MMU2 cells was also analysed 
by comparative genome hybridisation (CGH) to compare with SNP microarray data. 
Proteins previously determined to be involved in disease progression were quantified 
by Western blot and compared to array data. The SNP and CGH array both detected 
cytogenetic abnormalities commonly found in breast cancer: amplification of 
chromosomes 11q13-14.1, 17q and 20q containing cyclin D1, BCAS1 and 3 (Breast 
Cancer Amplified Sequence) and AIB1 (Amplified in Breast cancer) genes; losses at 
6q, 9p and X chromosomes which included ERα (Estrogen Receptor alpha) and 
p16INK4A genes. However the SNP chip array data additionally identified regions of 
loss of heterozygosity (LOH) followed by duplication of the remaining allele – 
uniparental disomy (UPD). Good concordance between SNP arrays and CGH 
analyses was observed, however there was poor correlation between gene copy 
number and protein levels between the cell lines. There were reductions in ERα, 
cyclin D1 and p27 protein levels whilst p21 protein levels were elevated in 
antiestrogen resistant MCF7 cell lines. Although protein levels varied there was no 
difference in gene copy number. This study shows SNP and CGH array analysis are 
powerful tools for analysis of allelic imbalance in breast cancer. However the 
antiestrogen resistant phenotype was likely to be due to changes in gene expression 
and protein degradation rather than in altered gene copy number.   
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Introduction  
Breast cancer is the most common malignancy in women in the United Kingdom and 
United States with 1 in 9 expected to develop the diseases during their lifetime 
(www.cancerreasearchuk.org). Antiestrogens, in particular tamoxifen, have been the 
main treatment for hormone dependent breast cancers and still remain the treatment of 
choice in the pre-menopausal setting. However, resistance is a major clinical problem 
as one third of estrogen dependent breast cancers are resistant to antiestrogens (1). 
Additionally, while many breast cancers may initially respond to antiestrogens, 
resistance often develops. An understanding of the genetic and proteomic changes 
which develop within a cancer cell that may confer antiestrogen resistance is therefore 
critical to the effective management of breast cancer.  
 
Several studies have characterised the genomes of breast cancer cell lines to detect 
common chromosomal aberrations in breast cancer and their possible implications in 
tumourigenesis. Allelic imbalances in tamoxifen resistant and sensitive breast cancers 
have been detected by karyotyping (2) and also comparative genomic hybridisation 
(CGH) (3, 4).  
 
Although CGH can be used on a genome wide scale to detect chromosomal gains and 
losses it has low resolution and allows for detection of genetic aberrations in the range 
of 1 to 20 Mb. Moreover, it cannot detect copy number changes coincident with 
regions of loss of heterozygosity (LOH). Advances in the understanding of the 
molecular pathology underlying many forms of malignancy has come from the 
mapping of minimal regions of LOH as these have often been associated with the 
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presence of a mutated oncogene on the remaining allele. Combining detection of both 
copy number changes and LOH allows for the recognition of a situation whereby the 
loss of one allele is followed by duplication of another, possibly mutated, allele 
(uniparental disomy, UPD).  
 
The more recent introduction of high density single nucleotide polymorphism (SNP) 
arrays, such as the Affymetrix 10 K GeneChip, enables genotyping of over 10,000 
SNPs in one assay, with analysis at 105 Kb resolution. This array contains probe sets 
which are specific for 11,555 unique genomic loci. The 10 K GeneChip array 
platform has been shown to be extremely accurate (99.5%), with high reproducibility 
(99.5%) and call rate (95%) (5). In this study we initially identified common allelic 
imbalances in 3 breast cancer cell lines of different origin – MCF7 (antiestrogen 
sensitive), T47D (intermediate antiestrogen sensitivity) and MDA-MB-231 
(antiestrogen resistant) (6) by SNP array analyses. Then, to investigate if any allelic 
imbalances could be detected which may have conferred the acquired antiestrogen 
resistance phenotype, we compared SNP chip data from parental MCF7 cells (MCF7N 
and MCF7L) to that from MCF7 cells with acquired antiestrogen resistance (MMU2, 
LCC9). The abnormalities found by SNP chip analyses in two of these cell lines 
(MCFL and MMU2) were verified by comparison to those detected by CGH studies. 
Finally, in order to assess the relevance of genomic data to the antiestrogen resistance 
phenotype, we measured the expression of proteins associated with proliferation and 
poor prognosis in antiestrogen sensitive and resistant MCF7 cells. 
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Materials and methods 
Cell lines and maintenance  
Antiestrogen sensitive MCF7 cells were routinely passaged at Newcastle University, 
Newcastle Upon Tyne and MCF7 and St James’s University Hospital, Leeds, UK and 
were designated MCF7N and MCF7L respectively. Two antiestrogen resistant cell 
lines were used: MMU2 cells were derived from MCF7L cells which had been grown 
continuously in 0.1 µM 4-hydroxytamoxifen until rendered resistant (7,8).  LCC9 
cells were a gift from Robert Clarke (Georgetown University School of Medicine) and 
were derived from MCF7 cells passaged at Georgetown University grown in 
increasing concentrations of the antiestrogen ICI 182,780 (9). T47D and MDA-MB-
231 cells were passaged at Newcastle University. All tissue culture and other reagents 
were of analytical grade and were purchased from Sigma-Aldrich Company Ltd 
(Dorset, UK) unless otherwise stated.  
Cells were incubated in RPMI 1640 medium supplemented with 10% (v/v) fetal 
bovine serum, penicillin (50 U/ml) and streptomycin (50 µg/ml) unless otherwise 
stated. MMU2 cells were grown in phenol red free RPMI 1640 medium and LCC9 
cells in phenol red free Dulbeccos Minimum Essential Medium (Gibco Invitrogen). 
Medium was supplemented with dextran charcoal stripped 10% FCS and penicillin 
(50 U/ml) and streptomycin (50 µg/ml). Before an experiment MMU2 cells 
underwent 2 passages in full RPMI 1640 medium and LCC9 cells underwent 2 
passages in full Minimum Essential Medium (Gibco Invitrogen. Paisley, UK). All 
cells were grown in fully supplemented media during experimental procedures.  
 
Single nucleotide polymorphism microarray analysis  
Total genomic DNA (minimum 250 ng) was extracted from thawed cell pellets using 
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the NucleonTM method (Scotlab, Strathclyde, Scotland) and sent to Medical Research 
Council Geneservice (Hinxton, Cambridge, United Kingdom) where it was digested 
with Xba I restriction enzyme, DNA fragments were ligated to adaptors which 
recognise cohesive four base pair overhangs. Ligated DNA fragments were amplified 
by PCR using primers that recognize the adaptor sequence. Amplified DNA was 
fragmented, end-labeled with a fluorescent tag and hybridized to the GeneChip® 
Mapping arrays (Affymetrix UK Ltd, High Wycombe, UK). The Affymetrix 
GeneChip® 10 K array contains probe sets directed against 11,555 unique genomic 
loci. Each SNP is represented by 40 different 25 bp oligonucleotides. Thus, the 10 K 
array offers genome analysis at a resolution of approx 105 Kb. Hybridisation to each 
probe was assessed using a gene chip scanner (Affymetrix) and data were analysed 
using the GeneChip® Operating Software (GCOS, Affymetrix), the GeneChip® DNA 
Analysis Software (GDAS, Affymetrix) and the GeneChip® Chromosome Copy 
Number Tool Software. The Affymetrix(r) GeneChip(r) Chromosome Copy Number 
Analysis Tool was used to estimate the probability of continuous homozygote calls. 
Values of less than 1 x 10-5 were considered significant, as previously described (10). 
Assessment of the intensity of hybridisation to the SNP and comparison to a reference 
set of 110 normal individuals were used to derive copy number estimates for an 
individual SNP, which have been integrated into the Chromosome Tool software 
programme (Affymetrix) (10). Data were exported to an Excel spreadsheet and 
probability of LOH and copy number plotted against chromosomal location.  
  
Comparative Genome Hybridisation (CGH) analysis  
Unless otherwise stated all reagents were provided in the Vysis Random Priming 
Labelling Kit and used according to the manufacturer’s instructions (Vysis, Inc, 
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USA). Genomic DNA was extracted from MCF7L and MMU2 cells.  DNA from male 
and female blood lymphocytes were used as negative controls. Test and reference 
DNA were hybridised and heated at 80°C for 10 minutes to denature the DNA.  These 
were cooled before placing on a Genosensor Amplicon 300 microarray for 72 
hours at 37°C. Arrays were washed with 50% formamide, 2X SSC at 40oC, (3 x 10 
minutes) then with 1XSSC at room temperature, (4 x 5 minutes) and rinsed in dH2O. 
DAPI was applied and a coverslip fixed. After 45 minutes incubation, arrays were 
imaged using GenoSensor Reader Software. Normal female versus normal male DNA 
arrays were analysed and a mean hybridisation ratio (green: red fluorescence ratio) 
calculated for all 287 clones on the GenoSensor Array 300 using Genosensor 
software. The mean intensity of the resulting Cy-3:Cy-5 ratios was calculated for 
triplicate spots. The male female chip was analysed in duplicate and an average 
intensity of 1.0 calculated. For subsequent experiments in which DNA from MCF7L  
and MMU2 test DNA (all labelled green) was hybridised to male reference DNA 
(labelled red), ratios of > 1 represented a relative gain of DNA in the test sample and 
ratios < 1 a relative loss of test DNA.  In addition, a CGH chip directly comparing 
DNA amplifications and deletions implicated in TAM resistance allowed 
quantification of the mean intensity of the ratio of Cy-3 labelled MMU2: Cy-5 
labelled MCF7L.  A 99% confidence interval was used throughout this study to test 
the significance of differentially expressed genes.  Chromosomes with amplifications 
or deletions >3 standard deviation from the mean of female/male reference were 
considered significant, since at the 99% confidence interval the value observed is 
outside the normal range (3).   
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Western blotting 
Exponentially growing cells were harvested by scraping into ice cold lysis buffer 
(20% (v/v) glycerol, 4% (w/v) SDS, 100 mM Tris HCl, pH 6.8). Lysates were passed 
through a 25G needle and heated to 85oC for 5 min before protein determination.  
Following the addition of an equal volume of sample buffer (0.001% (w/v) 
bromophenol blue, 100 mM dithiothreitol) 20 µg protein samples were resolved on 4-
20% polyacrylamide Tris/glycine gels (Invitrogen) and blotted onto Hybond enhanced 
chemiluminescence nitrocellulose membrane (Amersham) using Tris/glycine transfer 
buffer under recommended conditions.  Blots were blocked in TTBS buffer (20 mM 
Tris, 140 mM NaCl, 0.1 % (v/v) Tween-20, pH 7.6) containing 5% (w/v) non-fat 
dried milk for 1 h and then incubated overnight in antibody buffer (1% (w/v) non-fat 
dried milk in TTBS) containing primary antibody (total pRb (1:500, G3-245, BD 
Pharmingen. Devon, UK); Cyclin D1 (1:500, DCS-6, Dako. Cambridgeshire, UK); 
ERα (1:250, 1D5, Dako; actin (1:1000, AC-40, Sigma. Dorset, UK); CDK4 (1:500, C-
22, Santa Cruz. Wiltshire, UK); CDK2 (1:500, M2, Santa Cruz); Cyclin A (1:500, C-
19, Santa Cruz); Cyclin E (1:500, C-19, Santa Cruz); p27 (1:500, C-19, Santa Cruz); 
p21 (1:200, AB-1, Oncogene research products. Cambridge, UK). After three 15 min 
washes in TTBS buffer, blots were incubated with 1:5000 peroxidase-conjugated 
swine anti-rabbit secondary antibody (Dako), with the exception of blots using cyclin 
D1 or ERα primary antibodies where 1:1000 peroxidase-conjugated goat anti-mouse 
secondary antibody (Dako) was used.  Following three washes in TTBS, labelled 
proteins were detected using Supersignal West Dura extended duration enhanced 
chemiluminescence substrate (Pierce).  Chemiluminescence was detected by placing 
blots into a dark box with a CCD camera (Fuji LAS 3000, Raytek) and quantified 
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using Aida image analyser software. ERα protein was standardised to a purified ERα 
protein (Sigma) standard curve and fmoles/mg of cell lysate determined. 
 
 
Results  
Common abnormalities in MCF7, T47D and MDA-MB-231 breast cancer cell lines 
detected by SNP chip array 
In order to investigate if any allelic imbalances were important for the development of 
breast cancer we compared the SNP chip data in all of the cell lines analysed. Regions 
of gain and LOH in all breast cancer cell lines and MCF7 sub-lines are shown in 
Figure 1 and the common regions of gain, LOH and UPD are given in Tables 1, 2 and 
3.  The majority of allelic imbalances detected were unique to the individual cell lines. 
However, there were also several aberrations which were common to all 3 breast 
cancer cell lines and were therefore likely to be more typical of those genetic 
abnormalities detected in breast cancer (Table 1). These included LOH and haploid 
copy number at 6q25-ter the region containing the ERα gene (6q25.1). All breast 
cancer cell lines analysed in this study contained a haploid copy of 9p which contains 
the gene locus for p16INK4A (9p21) CDK4/6 inhibitor. Deletion of one copy of the X 
chromosome was observed in all the breast cancer cell lines tested. LOH was detected 
at 16q12-22, however no loss of material had occurred indicating UPD (Table 1). All 
of the breast cancer cell lines had increased copy number of several regions which are 
typically amplified in breast cancers (Table 1/ Figure 1). Amplification of the 
11q13.1-14.1 region which contained the cyclin D1, FGF19, 3 and 4 gene loci was 
also observed. The 17q23 locus which contained the BCAS3 (Breast Cancer 
Amplified Sequence 3) gene and ABC1 (Amplified Breast Cancer 1) gene loci also 
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had increased copy numbers. Likewise 20q12-13.2 was amplified which contained 
BCAS1 and AIB1 (Amplified in Breast) cancer genes.  These data also correlated well 
with other previous analyses carried out by the Cancer Genome project 
(www.sanger.ac.uk). 
 
Common abnormalities in MCF7 antiestrogen sensitive and resistant breast cancer 
cell lines detected by SNP chip array 
Since the cell lines showed significant heterogeneity we investigated the genomic 
changes which were only seen in MCF7 cells (Table 2). In addition to those described 
above MCF7 cell lines had amplification of 1q arm areas which contained the N-ras 
oncogene (1p13.2) and also the COX2 (1q31.1) gene. The p44S10 (3p14.1), c-myc 
(8q24) and the K-ras (12p11.2) gene locations were also found to be amplified. The 
region containing the CDK2 gene (12q13) was amplified which mediates the S phase 
entry. Also 15q21 which contains the MEK1 gene (15q22.1-22.3) and the P450arom 
(15q21.1) gene which encodes the aromatase enzyme.  
 
Reductions in copy number equalling haploid numbers were observed at the Rb gene 
locus (13q14.2). The CDK inhibitory protein p57Kip2 (11p15) gene region had 
reduction in SNP copy number as did the tyrosine kinase receptor EGFR gene locus 
(7p12-14). Normal copy number with LOH indicating UPD had occurred in MCF7 
cell lines at 3pter-14.1, 9q21.1, 18p and 21q22.12-22.3 (Table 2). No known obvious 
potential oncogenes linked with breast cancer tumourigeneis could be found in these 
regions. 
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Common abnormalities in MCF7 tamoxifen resistant breast cancer cell lines detected 
by SNP chip array 
We next compared the SNP data from the antiestrogen resistant MCF7 cells with the 
parental MCF7 cell lines in an attempt to discover if any regions of genetic imbalance 
could be involved in producing the acquired antiestrogen resistant phenotype. There 
were very few differences that were common to LCC9 and MMU2 cells and not 
found in MCF7N and MCF7L cell lines. In general the genotype of all the MCF7 cell 
lines was very similar confirming their common origin. However, we did detect gains 
of material at 18p11.32 and losses at 4q34.2-35.2 and 5p15 which were unique to the 
antiestrogen resistant MCF7 cell lines (Table 3). Unfortunately no genes located in 
these regions could be found which could be implicated in breast cancer 
tumourigenesis or antiestrogen resistance based on current knowledge. 
 
Comparison of SNP data to CGH data 
In addition to comparing the SNP array data to that seen at www.sanger.ac.uk we 
further validated our results by comparing to SNP chip data to CGH array analyses in 
the tamoxifen sensitive MCF7L and resistant MMU2 cell lines.  
 
Both the SNP chip and CGH array produced similar results (Figure 2). Losses at 1p, 
9p and amplifications at 3p, 16p, 16q and 21q were detected by both techniques. 
However there were a small number of conflicting differences in the abnormalities 
detected. Losses of genetic material on the X chromosome by SNP chip was not 
reported with CGH, similarly losses on 4p detected by CGH were not observed in 
SNP chip data (Figure 2). In contrast to the CGH array, SNP chip analyses also 
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highlighted regions of LOH associated with normal or increased copy number (UPD) 
(Figure 3). 
 
Protein expression in tamoxifen sensitive and resistant MCF7 cells 
The genomic analyses of the MCF7 cell lines demonstrated little change between the 
tamoxifen sensitive and resistant cell lines and did not explain the acquired 
antiestrogen resistance phenotype. We therefore looked at the expression of proteins 
which have previously been described to be involved in the regulation of estrogen and 
antiestrogen cell cycle control including ERα, cyclin D1, p27, p21, CDK4, 2, cyclin 
A, E and total pRb and compared their protein expression to the SNP and CGH copy 
number in the relative gene location. Protein was extracted from asynchronous 
exponentially growing cell cultures. ERα protein was most abundant in the tamoxifen 
sensitive MCF7N cell line, while T47D, LCC9 and MMU2 contained significantly 
reduced levels of ERα protein in comparison (2.7, 8 and 17 fold reductions 
respectively, quantified by densitometry). ERα protein was undetectable in MDA-
MB-231 cells (Figure 4b,c,d). Although there was variable ERα protein expression, 
all of the breast cancer cell lines tested had haploid copy number at the gene locus 
(6q25.1) by SNP and CGH chip analyses (Figure 4a). 
 
Further investigation of protein levels focused on antiestrogen sensitive MCF7 N cells 
and resistant MMU2 and LCC9 cells. These cell lines were from the same parental 
lineage and therefore were likely to be less genetically diverse, with differences in cell 
cycle protein levels more likely to be due to acquired antiestrogen resistance rather 
than differences in the parental origin of the cell lines. The levels of the CDK2 
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(12q13), cyclin E (19q12) and cyclin A (4q25-31) proteins were similar in each of the 
cell lines which also had the same gene copy numbers. However, there was 
considerable variation in cyclin D1 protein levels with LCC9 and MMU2 cells having 
around 2-fold reductions compared to the antiestrogen sensitive MCF7N cell line 
(Figure 5b; representative blot, Table 2 pooled densitometric analysis from 3 
independent experiments) despite having similar amplification (4n copy number) of 
the cyclin D1 gene locus (11q13) detected by SNP analyses (Figure 5a).  
All cells grew at the same rate (doubling time = 32 hr) and had similar cell cycle 
profiles (Neil Johnson, unpublished data) it is therefore likely that differences in 
protein levels were not due to accumulation in different cell cycle stages. 
 
In comparison to antiestrogen sensitive MCF7N cells both LCC9 and MMU2 cells had 
reduced p27 (2.3 and 1.5 fold reduction respectively) and increased p21 (3.4 and 2.8 
fold increase respectively) protein levels (Figure 4b/Table 4). However, no changes in 
gene copy number could be found at the p27 (12p13) and p21 (6p21.2) gene loci. The 
levels of total pRb protein were highest in the parental MCF7 cell line and were 
comparatively reduced in both MMU2 and LCC9 cells (1.6 and 1.4 fold reduction 
respectively) (Figure 4b/ Table) even though all MCF7 subtypes were haploid for the 
Rb gene locus (13q14.2). 
 
Discussion 
This study demonstrated the 10 K SNP chip array is a valuable method of detecting 
allelic imbalance in breast cancer cells and correlates well both with CGH analyses of 
the same cell lines and with reported CGH studies in breast cancer cell lines (3, 11, 
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12). In addition to CGH, the 10 K SNP chip array detected further regions of 
abnormalities due to the increased resolution of the genome it measures. The CGH 
array used in this study covered 300 gene loci giving a less intensive genome analyses 
compared to the SNP chip array which covered 11,555 SNPs in the genome.  
The main purpose of this study was to determine if genotypic changes detected by 
SNP and CGH array could explain the acquisition of the antiestrogen resistance 
phenotype. We compared array data from two parental and two antiestrogen resistant 
MCF7 cell lines. Analysing two parental and two resistant cell lines enabled us to 
discriminate between genetic changes caused by random genetic drift and those 
resulting from the antiestrogen treatment selective pressure. Genetic changes were 
also compared to protein levels which could be linked to the antiestrogen resistant 
phenotype. 
 
There was an extensive range of allelic imbalances in every one of the breast cancer 
cell lines detected by SNP chip array analyses. It was clear that the MCF7, T47D and 
MDA-MB-231 cell lines were isolated from different parental origins and MCF7N, 
MCF7L, MMU2 and LCC9 were from the same lineage. There were 3 regions of 
common allelic imbalances found in the antiestrogen resistant MCF7 cell lines that 
were not present in the antiestrogen sensitive MCF7 cells (Table 3). Alterations 
common to LCC9 and MMU2 that were different from MCF7 did not harbour genes 
that on the basis of current knowledge could explain the antiestrogen resistant 
phenotype. There was a similar number of different allelic imbalances detected 
between MCF7L and MCF7N (5 differences) or MMU2 and LCC9 (3 differences). The 
lack of consistent differences in the abnormalities detected in MMU2 and LCC9 cell 
lines compared to parental MCF7 cells suggested the differences were likely to be due 
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to random genetic drift rather than a cause or consequence of antiestrogen resistance. 
This is supported by the demonstration of genetic variation in every one of 11 
subpopulations of MCF7 cells analysed by CGH (14).  
 
There were many examples where LOH and haploid copy number were detected in all 
cell lines but there was a wide variation in protein levels between the cell lines. This 
was evident in a number of cases. It was previously believed there was no relationship 
between LOH at the gene locus and ERα gene expression (15). We have confirmed 
this observation as the cell lines we studied contained varying levels of ERα protein 
despite all having LOH at the ERα gene locus. Likewise the cyclin D1 gene was 
amplified in all of the cell lines to a similar degree, but the protein levels in the 
antiestrogen resistant MCF7 cell lines were reduced compared to the parental 
sensitive MCF7 cell line. The work reported here suggests acquired antiestrogen 
resistance in these cell lines was mediated at the mRNA and protein level rather than 
at the genomic level (Figure 6) confirming previous reports of increased mRNA and 
protein of growth factor signalling molecules as a primary feature of acquired 
antiestrogen resistance (16). 
 
In conclusion, our study demonstrates that whole genome SNP and CGH analysis are 
valuable tools in characterising markers of malignant progression. However, it is clear 
that there can be considerable variation in protein expression, despite an equivalent 
gene copy number between cell lines. It was likely that acquired antiestrogen 
resistance in MCF7 cell lines is mediated by alterations in gene expression and/or 
protein degradation rather than at the genomic level. 
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Table 1. Common allelic imbalances present in all breast cancer cell lines. 
 
Chromosome Gains Candidate genesa LOH UPD 
Candidate 
genesa 
6 6p12.3-12.1  6q25.2-ter  ERα, IGF2R 
8 
  8p22   
9 
  9p  p16 
11 11q13-14.1 cyclin D1, FGF19, 3, 4    
13 
  13q22-34   
14 14q11-22     
16 
   16q12-22  
17 17q23.2 BCAS3, ABC1    
20 20q13.2 BCAS1, AIB1, TOPO1    
X 
  X   
 
 
a
 Genes which could be implicated in tumourigenesis 
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Table 2. Common allelic imbalances present only in MCF7 cell lines. 
 
Chromosome Gains 
Candidate 
genesa LOH UPD 
Candidate 
genesa 
1 
1p13.2,  1q31.1, 
1q12-23 N-ras, COX2 1pter-21.1, 1q44  p58, SRC2 
3 3p25, 3p14.1, 3q26 P44S10  3pter-14.1  
7 7p14.1  7pter-14.3, 7p12.1  EGFR 
8 8q21-ter C-myc 8p   
9 9q21.1   9q21.1  
11 
  
11pter-15.3, 11q12.1, 
11q14.2-ter  p57 
12 12p11.2, 12q12-21 K-ras, MDM2, CDK2    
13 13q12.1-14.2 BRCA2 13q14.2-ter  Rb 
14 14q ERβ    
15 15q21.1-21.3 MEK1, CYP19 15q11.2-21.1   
16 16q22-ter  16q12-q22   
18 
  18q 18p  
20 20q     
21 21q22.12-22.3  21q11.2-22.13 
21q22.12-
22.3  
 
 
 
a
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Table 3. Common allelic imbalances present  in tamoxifen resistant MCF7 cells 
and not present in tamoxifen sensitive MCF7 cells. 
 
Chromosome Gains 
Candidate 
genes LOH UPD 
Candidate 
genes 
4 
  4q34.2-35.2   
5 
  5p15   
18 18p11.32     
 
 
Table 4. Fold changes in protein expression in antiestrogen-resistant variants of 
MCF7.  
Protein MMU2 LCC9 
CDK4 1 ± 0.1 0.96 ± 0.07 
CDK2 1.25 ± 0.36 0.95 ± 0.12 
Cyclin A 0.93 ± 0.17 0.84 ± 0.18 
Cyclin E 1.05 ± 0.26 0.85 ± 0.9 
Cyclin D1 0.5 ± 0.15 0.47 ± 0.05* 
p27 0.64 ± 0.15 0.43 ± 0.04* 
p21 2.84 ± 0.43* 3.38 ± 0.63* 
total pRb 0.70 ± 0.11 0.62 ± 0.08* 
 
Data are mean +/- standard deviation of densitometric anaysis of 3 independent 
experiments of the type shown in figure 5b expressed as a fraction of the expression in 
parental MCF7N cells. * Significantly different from MCF7N p < 0.05 
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Figure legends 
Figure 1 
SNP chip analysis of the genomes of breast cancer cell lines. Composite diagram 
showing chromosome gains and losses in MCF7N (A), MCF7L (B), MMU2 (C), LCC9 
(D), T47D (E) and MDA-MB-231 (F) cell lines. Gains are shown to the right of the 
chromosome and losses to the left. 
Figure 2 
Comparison of SNP chip analysis to CGH.  Diagram showing comparative 
chromosomal gains and losses in MCF7L (A) and MMU2 (B) detected by SNP chip 
(S) and CGH array (C). Gains are shown to the right of the chromosome and losses to 
the left. 
Figure 3 
Example of UPD detected by SNP chip analyses. Chromosome 21q11.2-22.13 
deletion with LOH of 21q. Amplification of 21q22.12-22.3 region with LOH 
indicating the occurrence of UPD in MCF7 cell line detected using 10K SNP arrays. 
a) representations of the areas of chromosome loss (to the left of 0) and gain (to the 
right of 0), 0 = normal copy number  b) the probability of LOH along the 
chromosome. A value of 1 represents a probability of less than 1 in 105  that a 
sequence of heterozygous calls will have happened by chance alone. 
 
Figure 4 
ERα gene copy number changes and protein expression. (a) SNP copy number at the 
ERα gene location (6q25.1 – white box) in MCF7N and MMU2 cell lines. 0 = 2n, -1 = 
1n, -2 = 0n, 2 =4n, 4 = 6n. (b and c) ERα protein levels were measured by western 
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blot in (b) MCF7N, T47D and MDA-MB-231, (c) MCF7N, LCC9 and MMU2 cells, 
representative blots shown. (d) Densitometric analyses of ERα protein levels, mean 
and S.D fmols/mg from 3 independent experiments was determined by comparing 
values to a purified ERα standard curve on the same membrane.  * Significantly 
different from MCF7N cells p < 0.05. 
 
Figure 5 
Cyclin D1 gene copy number changes and cell cycle proteins expression. (a) SNP 
copy number at the cyclin D1 gene location (11q13 – white box) in MCF7N and 
MMU2 cell lines. 0 = 2n, -1 = 1n, -2 = 0n, 2 =4n, 4 = 6n. (b) Protein expression of 
CDK4, CDK2, cyclin A, cyclin E, cyclin D1, p27, p21 and pRb measured by western 
blot in MCF7N, MMU2 and LCC9 cells. Representative blots shown, mean and S.D 
values from 3 independent experiments shown in Table 4. 
 
Figure 6 
Possible mechanisms of acquired antiestrogen resistance in breast cancer. Alterations 
in the levels and activity of cellular proteins is ultimately responsible for the 
development of tamoxifen resistance. Amplification or deletion of gene copies, 
alterations in transcriptional and translational regulation may contribute to altered 
protein production. Protein function or rate of degradation may be altered by changes 
in post-translational modifications. It is likely all of these factors contribute to 
produce tamoxifen resistance. 
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